AGIOS PHARMACEUTICALS, INC. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
AGIOS PHARMACEUTICALS, INC. (AGIO) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-24.
Discontinued › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2022-02-24
- AGIOS PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2021-12-31 was $0.00.
- AGIOS PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2021-09-30 was $0.00.
- AGIOS PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2021-06-30 was $0.00.
- AGIOS PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2021-03-31 was $0.00.
- AGIOS PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2021 was $0.00.
- AGIOS PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2020 was $0.00, a 100.00% decline from fiscal 2019.
- AGIOS PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2019 was $42.32M.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $0.00 derived: sum of 2 quarters · filed 2022-02-24 | $0.00 derived: sum of 3 quarters · filed 2022-02-24 | $0.00 10-K · filed 2022-02-24 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $0.00 derived: sum of 2 quarters · filed 2021-11-03 | $0.00 10-Q · filed 2021-11-03 | $0.00 derived: sum of 4 quarters · filed 2022-02-24 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | $0.00 10-Q · filed 2021-07-29 | $0.00 derived: sum of 3 quarters · filed 2022-02-24 | $0.00 derived: sum of 4 quarters · filed 2022-02-24 |
| 2021-03-31 | $0.00 10-Q · filed 2021-04-29 | $0.00 derived: sum of 2 quarters · filed 2022-02-24 | $0.00 derived: sum of 3 quarters · filed 2022-02-24 | $0.00 derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $0.00 derived: sum of 2 quarters · filed 2022-02-24 | $0.00 derived: sum of 3 quarters · filed 2022-02-24 | $0.00 10-K · filed 2022-02-24 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $0.00 derived: sum of 2 quarters · filed 2021-11-03 | $0.00 10-Q · filed 2021-11-03 | $0.00 derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | $0.00 10-Q · filed 2021-07-29 | $0.00 derived: sum of 3 quarters · filed 2022-02-24 | -$534.00K derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | $0.00 10-Q · filed 2021-04-29 | $0.00 derived: sum of 2 quarters · filed 2022-02-24 | -$534.00K derived: sum of 3 quarters · filed 2022-02-24 | $42.32M derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | -$534.00K derived: sum of 2 quarters · filed 2022-02-24 | $42.32M derived: sum of 3 quarters · filed 2022-02-24 | $42.32M 10-K · filed 2022-02-24 |
| 2019-09-30 | -$534.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $42.32M derived: sum of 2 quarters · filed 2020-11-05 | $42.32M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $42.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-30 | $42.86M 10-Q · filed 2020-07-30 | ||
| 2019-03-31 | $0.00 10-Q · filed 2020-04-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |